ABSTRACT
Blood volume analysis provides a quantitative volume assessment in patients with equivocal or discordant clinical findings. Reports on its use in mechanical circulatory support are limited and it has never been described in patients with a total artificial heart. Our series demonstrates that patients supported with total artificial heart as a bridge to transplant have significant reductions in red blood cell volume and heterogeneous adaptations in their total blood volume and plasma volume. Pathologic derangements in our patient's total blood volume were targeted to restore euvolemia.
ABSTRACT
Objectives: Heart failure impacts patients' functional capabilities, ultimately leading to frailty. The use of a left ventricular assist device (LVAD) is acceptable as both destination therapy and bridge to transplant in heart failure management. We aim to evaluate the prognostic value of the Clinical Frailty Scale (CFS) on outcomes in older patients undergoing implantation of LVAD. Methods: We conducted a retrospective chart review of patients ≥ 60 years old that underwent LVAD implantation at our medical center from May 1, 2018, to October 30, 2020. CFS was retrospectively assigned before LVAD placement and CFS scores > 4 was considered frail. Kaplan-Meier curves and Cox regression were used to analyze 1-year survival estimates. Results: Forty percent of the cohort was classified as frail according to CFS. Thirty-day re-admission rates were comparable between frail and non-frail patients (46% vs 35%; P = 0.419). 1-year survival was lower in the frail vs non-frail group (log rank, P = 0.017). On Cox analysis, only frailty was associated with 1-year post-intervention mortality (hazard ratio [HR] = 5.64, 95% confidence interval [CI] = 1.131-28.212; P = 0.035). Conclusions: CFS-defined frailty was associated with increased risk of 1-year mortality after LVAD implantation. CFS may be a valuable tool in the frailty assessment for risk stratification of patients undergoing LVAD implantation. Multicenter studies are required to validate these findings.
ABSTRACT
Device-related hemolysis leading to anemia is a recognized chronic complication of a left ventricular assist device (LVAD). With the increased usage of the LVAD in the management of end-stage heart failure, an increased number of complications are being recognized. We present a case where a combination of elevated mean arterial pressure and development of aortic regurgitation resulted in increased hemolysis, power spikes, and anemia, mimicking device thrombus, resulting in a diagnostic dilemma.
Subject(s)
Aortic Valve Insufficiency/complications , Heart-Assist Devices/adverse effects , Hemolysis , Thrombosis/etiology , Humans , Male , Middle AgedSubject(s)
Antiphospholipid Syndrome/complications , Endocarditis/diagnostic imaging , Endocarditis/etiology , Thrombosis/diagnostic imaging , Thrombosis/etiology , Antiphospholipid Syndrome/blood , Antiphospholipid Syndrome/diagnosis , Echocardiography , Humans , Ischemic Attack, Transient/etiology , Lupus Coagulation Inhibitor/blood , Male , Middle AgedABSTRACT
End-stage renal failure is often considered a relative contraindication for total artificial heart implantation due to the increased risk of mortality after transplantation. We report the successful treatment of a patient having heart and renal failure with the CardioWest (SynCardia Inc, Tucson, AZ) total artificial heart for bridge-to-cardiac transplantation of a heart and kidney.